97 related articles for article (PubMed ID: 1647806)
1. PGD2 and its mimetic ZK 110.841 are potent inhibitors of receptor-mediated activation of human neutrophils.
Ney P; Schrör K
Eicosanoids; 1991; 4(1):21-8. PubMed ID: 1647806
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human platelets and polymorphonuclear neutrophils by the potent and metabolically stable prostaglandin D2 analog ZK 118.182.
Darius H; Michael-Hepp J; Thierauch KH; Fisch A
Eur J Pharmacol; 1994 Jun; 258(3):207-13. PubMed ID: 7522176
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI2.
Hecker G; Ney P; Schrör K
Naunyn Schmiedebergs Arch Pharmacol; 1990 Apr; 341(4):308-15. PubMed ID: 2159112
[TBL] [Abstract][Full Text] [Related]
4. Potent inhibition of leukotriene (LT) B4 release from human polymorphonuclear leukocytes (PMN) by the PGE1-analogue OP-1206.
Ney P; Hecker G; Schröder H; Schrör K
Biomed Biochim Acta; 1988; 47(10-11):S186-9. PubMed ID: 2470354
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.
Ney P; Braun M; Szymanski C; Bruch L; Schrör K
Eicosanoids; 1991; 4(3):177-84. PubMed ID: 1663381
[TBL] [Abstract][Full Text] [Related]
6. Leukocyte inhibitory factor (LIF) potentiates human macrophage aggregation and activation responses to calcium ionophore A23187 and directly induces leukotriene B4 and thromboxane A2 release.
Conti P; Barbacane RC; Reale M; Panara MR; Placido FC; Mier JW; Castracane JM; Dempsey RA
Biotechnol Ther; 1993; 4(3-4):239-52. PubMed ID: 8292972
[TBL] [Abstract][Full Text] [Related]
7. Involvement of leukotriene B4 and platelet-activating factor in cytokine priming of human polymorphonuclear leucocytes.
Stewart AG; Harris T; De Nichilo M; Lopez AF
Immunology; 1991 Feb; 72(2):206-12. PubMed ID: 1849872
[TBL] [Abstract][Full Text] [Related]
8. Production of platelet-activating factor by stimulated human polymorphonuclear leukocytes. Correlation of synthesis with release, functional events, and leukotriene B4 metabolism.
Sisson JH; Prescott SM; McIntyre TM; Zimmerman GA
J Immunol; 1987 Jun; 138(11):3918-26. PubMed ID: 3035016
[TBL] [Abstract][Full Text] [Related]
9. Pro-inflammatory and anti-inflammatory effects of the stable prostaglandin D2 analogue, ZK 118.182.
Pons F; Williams TJ; Kirk SA; McDonald F; Rossi AG
Eur J Pharmacol; 1994 Aug; 261(3):237-47. PubMed ID: 7813544
[TBL] [Abstract][Full Text] [Related]
10. The prostaglandin paradox: additive inhibition of neutrophil function by aspirin-like drugs and the prostaglandin E1 analog misoprostol.
Kitsis EA; Weissmann G; Abramson SB
J Rheumatol; 1991 Oct; 18(10):1461-5. PubMed ID: 1662723
[TBL] [Abstract][Full Text] [Related]
11. Viscolin, a new chalcone from Viscum coloratum, inhibits human neutrophil superoxide anion and elastase release via a cAMP-dependent pathway.
Hwang TL; Leu YL; Kao SH; Tang MC; Chang HL
Free Radic Biol Med; 2006 Nov; 41(9):1433-41. PubMed ID: 17023270
[TBL] [Abstract][Full Text] [Related]
12. Modulation of the heterogeneous membrane potential response of neutrophils to N-formyl-methionyl-leucyl-phenylalanine (FMLP) by leukotriene B4: evidence for cell recruitment.
Fletcher MP
J Immunol; 1986 Jun; 136(11):4213-9. PubMed ID: 3009618
[TBL] [Abstract][Full Text] [Related]
13. Beta-adrenergic modulation of the polymorphonuclear leukocyte respiratory burst is dependent upon the mechanism of cell activation.
Nielson CP
J Immunol; 1987 Oct; 139(7):2392-7. PubMed ID: 2821113
[TBL] [Abstract][Full Text] [Related]
14. Anti-inflammatory effects of prostaglandin E1: in vivo modulation of the formyl peptide chemotactic receptor on the rat neutrophil.
Fantone JC; Marasco WA; Elgas LJ; Ward PA
J Immunol; 1983 Apr; 130(4):1495-7. PubMed ID: 6300229
[TBL] [Abstract][Full Text] [Related]
15. Release of leukotriene B4 from human neutrophils and its relationship to degranulation induced by N-formyl-methionyl-leucyl-phenylalanine, serum-treated zymosan and the ionophore A23187.
Palmer RM; Salmon JA
Immunology; 1983 Sep; 50(1):65-73. PubMed ID: 6309653
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of cytoskeletal rearrangement by botulinum C2 toxin amplifies ligand-evoked lipid mediator generation in human neutrophils.
Grimminger F; Sibelius U; Aktories K; Suttorp N; Seeger W
Mol Pharmacol; 1991 Oct; 40(4):563-71. PubMed ID: 1656192
[TBL] [Abstract][Full Text] [Related]
17. Modulation of leukotriene release from human polymorphonuclear leucocytes by PMA and arachidonic acid.
Raulf M; König W
Immunology; 1988 May; 64(1):51-9. PubMed ID: 2838420
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin E1 inhibits N-formyl-methionyl-leucyl-phenylalanine-mediated depolarization responses by decreasing the proportion of responsive cells without affecting chemotaxin-induced forward light scatter changes.
Fletcher MP
J Immunol; 1987 Dec; 139(12):4167-73. PubMed ID: 3693900
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of calcimycin-induced stimulation of cytosolic calcium in human PMN by a LTB4 receptor antagonist.
Heckenberger R; Schrör K
Eicosanoids; 1992; 5 Suppl():S23-5. PubMed ID: 1333252
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of platelet function by polymorphonuclear leukocytes.
Zatta A; Prosdocimi M; Bertelé V; Bazzoni G; Del Maschio A
J Lab Clin Med; 1990 Nov; 116(5):651-60. PubMed ID: 2146349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
